[Abstract] Cancer Res 81 (4): A-GS3-00, 2021.Also available online.
Last accessed April 24, 2025.
Nitz U, Gluz O, Clemens M, et al.: West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
J Clin Oncol 37 (10): 799-808, 2019.[PUBMED Abstract] Ma XJ, Wang Z, Ryan PD, et al.: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
Cancer Cell 5 (6): 607-16, 2004.[PUBMED Abstract] Sgroi DC, Carney E, Zarrella E, et al.: Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.